RT Journal Article
SR Electronic
T1 T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20202929
DO 10.1101/2020.09.28.20202929
A1 Ogbe, Ane
A1 Kronsteiner, Barbara
A1 Skelly, Donal T.
A1 Pace, Matthew
A1 Brown, Anthony
A1 Adland, Emily
A1 Adair, Kareena
A1 Akhter, Hossain Delowar
A1 Ali, Mohammad
A1 Ali, Serat-E
A1 Angyal, Adrienn
A1 Ansari, M. Azim
A1 Arancibia-Cárcamo, Carolina V
A1 Brown, Helen
A1 Chinnakannan, Senthil
A1 Conlon, Christopher
A1 de Lara, Catherine
A1 de Silva, Thushan
A1 Dold, Christina
A1 Dong, Tao
A1 Donnison, Timothy
A1 Eyre, David
A1 Flaxman, Amy
A1 Fletcher, Helen
A1 Gardner, Joshua
A1 Grist, James T.
A1 Hackstein, Carl-Philipp
A1 Jaruthamsophon, Kanoot
A1 Jeffrey, Katie
A1 Lambe, Teresa
A1 Lee, Lian
A1 Li, Wenqin
A1 Lim, Nicholas
A1 Matthews, Philippa C.
A1 Mentzer, Alexander J.
A1 Moore, Shona C.
A1 Naisbitt, Dean J
A1 Ogese, Monday
A1 Ogg, Graham
A1 Openshaw, Peter
A1 Pirmohamed, Munir
A1 Pollard, Andrew J.
A1 Ramamurthy, Narayan
A1 Rongkard, Patpong
A1 Rowland-Jones, Sarah
A1 Sampson, Oliver
A1 Screaton, Gavin
A1 Sette, Alessandro
A1 Stafford, Lizzie
A1 Thompson, Craig
A1 Thomson, Paul J
A1 Thwaites, Ryan
A1 Vieira, Vinicius
A1 Weiskopf, Daniela
A1 Zacharopoulou, Panagiota
A1 ,
A1 ,
A1 Turtle, Lance
A1 Klenerman, Paul
A1 Goulder, Philip
A1 Frater, John
A1 Barnes, Eleanor
A1 Dunachie, Susanna
YR 2020
UL http://medrxiv.org/content/early/2020/09/29/2020.09.28.20202929.abstract
AB A major issue in identification of protective T cell responses against SARS-CoV-2 lies in distinguishing people infected with SARS-CoV-2 from those with cross-reactive immunity generated by exposure to other coronaviruses. We characterised SARS-CoV-2 T cell immune responses in 168 PCR-confirmed SARS-CoV-2 infected subjects and 118 seronegative subjects without known SARS-CoV-2 exposure using a range of T cell assays that differentially capture immune cell function. Strong ex vivo ELISpot and proliferation responses to multiple antigens (including M, NP and ORF3) were found in those who had been infected by SARS-CoV-2 but were rare in pre-pandemic and unexposed seronegative subjects. However, seronegative doctors with high occupational exposure and recent COVID-19 compatible illness showed patterns of T cell responses characteristic of infection, indicating that these readouts are highly sensitive. By contrast, over 90% of convalescent or unexposed people showed proliferation and cellular lactate responses to spike subunits S1/S2, indicating pre-existing cross-reactive T cell populations. The detection of T cell responses to SARS-CoV-2 is therefore critically dependent on the choice of assay and antigen. Memory responses to specific non-spike proteins provides a method to distinguish recent infection from pre-existing immunity in exposed populations.Competing Interest StatementDWE declares lecture fees from Gilead, outside the submitted work AS is listed as inventor on patent application no. 63/012,902, submitted by La Jolla Institute for Immunology, that covers the use of the megapools and peptides thereof for therapeutic and diagnostic purposes. AS is a consultant for Gritstone and Flow Pharma and Avalia.Funding StatementThe views expressed in this article are those of the authors and not necessarily those of the National Health Service (NHS), the National Institutes for Health Research (NIHR), or the Medical Research Council (MRC). This work was supported by the UK Coronavirus Immunology Consortium (UK-CIC). MAA is supported by a Wellcome Trust Sir Henry Dale Fellowship (220171/Z/20/Z). EB and PK are NIHR Senior Investigators and PK is funded by WT109965MA. TD is funded by the Medical Research Council (MRC), UK: Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS), China (grant number: 2018-I2M-2-002). DWE is a Robertson Foundation Fellow. AJM was supported by the Medical Research Council [grant MC_PC_19059] and the National Institutes for Health and Oxford Biomedical Research Centre. PK is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. PK is based at the University of Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England. PCM is funded by a Wellcome intermediate fellowship, ref. 110110/Z/15/Z. The work by AS and DW was funded by National Institutes of Health contract Nr. 75N9301900065. DS is supported by the NIHR Academic Clinical Fellow programme in Oxford. OS is funded by the Wellcome Trust Infection, Immunology, and Translational Medicine programme (Grant: 108869/Z/15/Z). LT is supported by the Wellcome Trust (grant number 205228/Z/16/Z) and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. LT is based at University of Liverpool. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:research ethics committee (REC) at Yorkshire & The Humber - Sheffield (GI Biobank Study 16/YH/0247).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made public upon publication of the results in a peer-reviewed journal